PATENT CLAIM ANALYSIS

Application Number: 16068332
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "312000"]

Abstract:
Provided in the present invention are a use of quinoline derivatives for treating oesophageal cancer and a treatment method, a pharmaceutical composition and a kit thereof. The 1-[[[4-(4-fluoro-2-methyl-1H-indole-5-yl)oxy-6-methoxyquinoline-7-yl]oxy]methyl]cyclopropylamine provided by the present invention can effectively treat oesophageal cancer, and reduce the sum of the diameters of patient's target lesions.

Claim (Index 25):
The method of  claim 6 , wherein the daily administration dosage of Compound or the pharmaceutically acceptable salt thereof is 12 mg.

Metadata:
- Claim Count in Document: 37.0
- Percentile: 95.0
- Lexical Diversity: 1.41667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12267321', '15533873', '15719636', '11130295', '15315647']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7599633870247807
- 35 USC 102 Novelty (BERT): 0.4965320643409522
- Combined Prediction Score: 0.7336202547563979
- Mean Citation Score: 188.46138
- Max Citation Score: 190.91985
- Similarity Product: 123.30947751128376

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test